Journal ArticleDOI
Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for Parkinson's disease.
TLDR
Savinamide is a highly selective and reversible monoamine oxidase B inhibitor introduced in the European Union, Japan, and the United States as an adjunctive agent to levodopa in patients with motor fluctuation as mentioned in this paper.Abstract:
Introduction While levodopa is still the most effective treatment for Parkinson's disease, concerns about long-term complications such as wearing-off and dyskinesia with levodopa usage remain. Areas covered : Safinamide is a highly selective and reversible monoamine oxidase B inhibitor introduced in the European Union, Japan, and the United States as an adjunctive agent to levodopa in PD patients with motor fluctuation. This review outlines the pharmacological properties, therapeutic effects, and tolerability of safinamide as an adjunct to levodopa in patients with advanced PD. Efficacy and safety findings from double-blind and placebo-controlled clinical trials for safinamide as an adjunct therapy to levodopa for PD are summarized. Expert opinion : Safinamide was well tolerated as a treatment for PD, and there was no significant difference in the frequency and severity of adverse events between the safinamide and placebo groups. It was also suggested that safinamide had a beneficial effect on the accompanying non-motor symptoms such as PD-related pain. Safinamide may exhibit neuroprotective effects through antioxidant and anti-glutamate effects, and research on the disease-modifying effect of PD is desired in the future.read more
Citations
More filters
Journal ArticleDOI
Neuroprotective effect of Ginsenoside Re against neurotoxin-induced Parkinson's disease models via induction of Nrf2
TL;DR: The findings of the present study suggest that Re protects neurons against Rot-induced mitochondrial dysfunction and oxidative damage, at least in part, by inducing Nrf2/heme oxygenase-1 expression and activation of the dual PI3K/AKT and ERK pathways.
Journal ArticleDOI
Long-term effects of safinamide adjunct therapy on levodopa-induced dyskinesia in Parkinson’s disease: post-hoc analysis of a Japanese phase III study
TL;DR: In this paper , the long-term effects of safinamide on the course of dyskinesia and efficacy outcomes using data from a phase III, open-label 52-week study of Japanese patients with Parkinson's disease (PD) with wearing-off.
Journal ArticleDOI
Collective Expert Perspectives on the Use of Safinamide as Adjunctive Therapy for Parkinson’s Disease: Online-Based Delphi Survey
TL;DR: In this article , the Delphi panel approach was used to summarize the opinions of panelists, and the consensus was defined as 80% or more agreement between panelists for each scenario at the final round.
Journal ArticleDOI
Safinamide as an Adjunct to Levodopa in Asian and Caucasian Patients With Parkinson’s Disease and Motor Fluctuations: A Post Hoc Analysis of the SETTLE Study
Roongroj Bhidayasiri,Takayuki Ishida,Takanori Kamei,Ryan Edbert Husni,Ippei Suzuki,Shey-Lin Wu,Jin Whan Cho +6 more
TL;DR: Savinamide is a selective, reversible monoamine oxidase B inhibitor with demonstrated efficacy and tolerability in placebo-controlled studies and is clinically useful for patients with motor fluctuations as mentioned in this paper .
References
More filters
Book ChapterDOI
Enantioselective recognition of two anticonvulsants, FCE 26743 and FCE 28073, by MAO, and relationship between MAO-B inhibition and FCE 26743 concentrations in rat brain.
M. Strolin Benedetti,P. Tocchetti,Maurizio Rocchetti,M. Martignoni,P. Marrari,Italo Poggesi,Philippe Dostert +6 more
TL;DR: In the in vitro studies where the rat brain homogenates were studied, FCE 26743 was found to be a potent inhibitor of MAO-B and a weak inhibitor ofMAO-A, while FCE 28073 was approximately 10-times less potent.
Journal ArticleDOI
Pain in Parkinson's disease: facts and uncertainties.
Angelo Antonini,Michele Tinazzi,Giovanni Abbruzzese,Alfredo Berardelli,Kallol Ray Chaudhuri,Giovanni Defazio,Joaquim J. Ferreira,Pablo Martinez-Martin,Claudia Trenkwalder,O. Rascol +9 more
TL;DR: An expert group of clinicians with relevant research experience met to review the existing evidence and identify gaps in understanding leading towards an optimized therapy of pain in Parkinson's disease.
Journal ArticleDOI
Monoamine oxidase B inhibitors for early Parkinson's disease
TL;DR: MAO-B inhibitors do not appear to delay disease progression but may have a beneficial effect on motor fluctuations, but at present it is not felt these drugs can be recommended for routine use in the treatment of early Parkinson's disease.
Journal ArticleDOI
A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease
TL;DR: A drug class review comparing all available monoamine oxidase type B (MAO‐B) inhibitors in a multiple treatment comparison of rasagiline, selegiline and safinamide is performed.
Journal ArticleDOI
Pain in Parkinson's disease: new concepts in pathogenesis and treatment.
Katarina Rukavina,Valentina Leta,Carolina Sportelli,Yazead Buhidma,Susan Duty,Marzia Malcangio,Kallol Ray Chaudhuri +6 more
TL;DR: The most recent evidence on mechanisms underlying pathological nociceptive processing in Parkinson's disease patients, as well as novel treatment strategies are discussed, including DBS, physiotherapie, and nondopaminergic pharmacological therapies and nonpharmacological interventions.